Company Overview

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of precision bacteriophage (“phage”) therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company operates within the biotechnology and anti-infectives industries, with a core emphasis on alternatives to traditional antibiotics. Armata’s technology leverages naturally occurring bacteriophages that selectively target pathogenic bacteria while sparing beneficial microbiota, positioning the company within the emerging field of microbiome-sparing therapeutics.

The company’s primary revenue drivers are research and development activities related to its proprietary phage-based product candidates, as Armata does not generate commercial product revenue. Its key customer and stakeholder base includes healthcare systems, pharmaceutical partners, government agencies, and patients affected by chronic and drug-resistant infections. Armata traces its origins to phage research conducted in academic and clinical settings and evolved into a public company through its merger with a special purpose acquisition company in 2021, enabling expanded clinical development and capital access.

Business Operations

Armata’s operations are centered on its Phage Therapeutics Platform, which includes discovery, engineering, and manufacturing capabilities designed to produce both natural and synthetic phage cocktails. The company’s leading development programs target Pseudomonas aeruginosa infections in cystic fibrosis and non-cystic fibrosis bronchiectasis, as well as other high-unmet-need bacterial indications. Revenue generation is currently limited to collaboration payments, grants, and licensing-related income, with the majority of expenditures allocated to clinical trials and platform development.

Operationally, Armata conducts research and development primarily in the United States, supported by internal laboratories and manufacturing capabilities for clinical-grade phage production. The company has engaged in strategic collaborations with academic institutions, government-funded research initiatives, and pharmaceutical partners to advance clinical studies and expand its phage library. Its wholly owned subsidiary, Armata Pharmaceuticals (Israel) Ltd., supports research activities and scientific collaboration.

Strategic Position & Investments

Armata’s strategic direction is focused on advancing its lead clinical candidates through mid- to late-stage clinical development while expanding its phage discovery and synthetic biology capabilities. Growth initiatives include broadening its pipeline to address additional antibiotic-resistant pathogens and enhancing manufacturing scalability to support future commercialization. The company has made targeted investments in proprietary phage engineering technologies designed to improve potency, durability, and resistance management.

Rather than pursuing large-scale acquisitions, Armata has emphasized internal R&D investment and selective partnerships. Its portfolio includes multiple preclinical and clinical-stage assets derived from its core platform, and the company is actively involved in emerging areas such as precision antimicrobials and personalized phage therapies. These efforts position Armata as a specialized player within the anti-infectives space, differentiated by its focus on targeted bacterial eradication.

Geographic Footprint

Armata is headquartered in Los Angeles, California, which serves as the center for corporate leadership, research strategy, and clinical operations. The company’s primary operational footprint is in North America, where it conducts most of its clinical trials and regulatory interactions. Through Israel, Armata maintains an international research presence that supports phage discovery and development activities.

While Armata does not yet have commercial operations across multiple continents, its clinical programs and partnerships have global relevance, particularly in regions facing rising antibiotic resistance. The company’s technologies are intended for international deployment pending regulatory approvals, and its intellectual property portfolio is structured to support future global commercialization.

Leadership & Governance

Armata is led by an executive team with experience in biotechnology, pharmaceuticals, and clinical development, guided by a strategic vision centered on addressing antimicrobial resistance through precision therapeutics. The leadership emphasizes scientific rigor, regulatory alignment, and long-term value creation through platform innovation rather than short-term commercialization.

Key executives include:

• Deborah A. Birx, M.D. – Chief Executive Officer and Director
• Michael L. Watson – Chief Financial Officer
• Andrew L. H. Leung, Ph.D. – Chief Scientific Officer
• Michael A. Karavolos – Chief Operating Officer
• Robert W. T. Mitchell, Ph.D. – Senior Vice President, Research & Development

The company’s governance structure includes an independent board of directors with backgrounds in healthcare, finance, and life sciences, supporting oversight of clinical strategy, capital allocation, and regulatory compliance.